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Abstract
Aims: The human branched-chain aminotransferase proteins (hBCATm and hBCATc) are regulated through
oxidation and S-nitrosation. However, it remains unknown whether they share common redox characteristics to
enzymes such as protein disulfide isomerase (PDI) in terms of regulating cellular repair and protein misfolding.
Results: Here, similar to PDI, the hBCAT proteins showed dithiol-disulfide isomerase activity that was medi-
ated through an S-glutathionylated mechanism. Site-directed mutagenesis of the active thiols of the CXXC
motif demonstrates that they are fundamental to optimal protein folding. Far Western analysis indicated that
both hBCAT proteins can associate with PDI. Co-immunoprecipitation studies demonstrated that hBCATm
directly binds to PDI in IMR-32 cells and the human brain. Electron and confocal microscopy validated the
expression of PDI in mitochondria (using Mia40 as a mitochondrial control), where both PDI and Mia40 were
found to be co-localized with hBCATm. Under conditions of oxidative stress, this interaction is decreased,
suggesting that the proposed chaperone role for hBCATm may be perturbed. Moreover, immunohistochemistry
studies show that PDI and hBCAT are expressed in the same neuronal and endothelial cells of the vasculature of
the human brain, supporting a physiological role for this binding. Innovation: This study identifies a novel
redox role for hBCAT and confirms that hBCATm differentially binds to PDI under cellular stress. Conclusion:
These studies indicate that hBCAT may play a role in the stress response of the cell as a novel redox chaperone,
which, if compromised, may result in protein misfolding, creating aggregates as a key feature in neurodegen-
erative conditions such as Alzheimer’s disease. Antioxid. Redox Signal. 00, 000–000.
Introduction
Optimal cellular function depends on the interplay ofnumerous repair and chaperone systems. Repair en-
zymes such as thioredoxin, glutaredoxin, and the disulfide
isomerase catalyst, protein disulfide isomerase (PDI) repre-
sent the thioredoxin superfamily that mediates a co-
ordinated adaptive response to changes in the cellular redox
environment (5, 45). These oxidoreductases, characterized by
their conserved catalytic recognition sequence, the CXXC
motif, function to repair and chaperone proteins through di-
thiol-disulfide exchange mechanisms (7, 21, 27, 51, 70). PDI
(EC 5.3.4.1), largely located in the endoplasmic reticulum
(ER), is a versatile protein that can catalyze the formation and
breakage of disulfide bonds, facilitating correct refolding of
proteins by rearranging the pattern of disulfide bonds (26, 68).
In cell models, proteins such as PDI are proposed to act
by alleviating the build-up of mis-folded proteins, preventing
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neurotoxicity (58). Should these protection mechanisms
fail, mis-folded proteins accumulate creating aggregates,
which can interfere with cell function by contributing to
the pathogenesis of neurodegenerative conditions such as
Alzheimer’s disease (AD) (62, 62, 71).
The human branched-chain aminotransferase proteins
(hBCATs) (EC 2.6.1.42) catalyze the reversible transamination
of the a-amino group of the branched-chain amino acids to a-
ketoglutarate, forming their respective branched chain a-keto
acids and glutamate (30, 32). The branched chain a-keto acids
are further metabolized through irreversible decarboxylation
that is catalyzed by the branched chain keto acid dehydro-
genase complex (BCKDH) (25). Although other isoforms exist,
the cytosolic (hBCATc) and mitochondrial (hBCATm) form
predominate, with hBCATm expressed in most tissues and
hBCATc primarily expressed in the brain and peripheral
nervous system (22, 29, 30, 57). The hBCAT proteins operate
as homodimers with a subunit molecular mass of 41.73 and
43.40 kDa for hBCATm and hBCATc, respectively (20).
Transamination by the BCAT proteins in the brain contributes
to more than 30% of de novo brain glutamate (30). In human
and rat brain, hBCATc is specific to glutamatergic and GA-
BAergic neurons, where expression is predominantly in the
soma and proximal dendrites, in keeping with its role in
contributing to the storage and metabolic pools of glutamate,
which is, in turn, decarboxylated in GABAergic neurons to
form GABA (22, 57). The mitochondrial isoform is localized
specifically to the human brain vasculature with localized
neuronal staining, where a role in brain glutamate metabo-
lism has been suggested (28); whereas it is located in astro-
cytes of rat models (8, 9, 12).
Unique to the mammalian BCAT proteins is a conserved
CXXC motif, which is*10 A˚ from the active site (23, 72). X-
ray crystallography and biochemical studies of overexpressed
hBCAT have shown that these thiol groups confer redox-
linked regulation to the hBCAT proteins and that the active
and inactive form results from the reduced and oxidized
CXXCmotif, respectively (18, 23, 72). In response to oxidation,
the thiol at the N-terminal position acts as a redox sensor,
whereas the C-terminal residue permits reversible regulation
through the formation of a disulfide bond via a sulphenic acid
intermediate, resulting in a loss of hBCAT activity (16, 17).
X-ray crystallography studies and kinetic analysis demon-
strated that the predominant effect of oxidation was on the
second half reaction rather than on the first half reaction,
where disruption of the CXXC center results in altered
substrate orientation and an unprotonated pyridoxal mono-
phosphate amino group, thus rendering the enzyme catalyti-
cally inactive (73). Both isoformswere differentially inactivated
through S-nitrosation; however, prolonged exposure to S-
nitrosoglutathione (GSNO) resulted in a shift from S-nitrosation
to S-glutathionylation, suggesting that S-glutathionylation
plays a protective role in preserving hBCAT function during
periods of cellular stress (13). Physiologically, the reduced
state of the CXXC motif of the hBCAT proteins is essential for
the binding of hBCATm to the E1 subunit of the BCKDH
complex, facilitating substrate channeling of the a-keto acids
(33). In a separate study, using extracts from neuronal cells,
hBCATc was shown to have specific peroxide-related redox
associations with several proteins known to be involved in
protein cell signaling, indicating a novel role for hBCATc in
cellular redox control (15). However, neither the cellular
mechanisms that govern this redox sensitivity nor their redox
substrates are completely understood.
In these studies, we have found that the hBCAT proteins
have dithiol-disulfide isomerase activity that is regulated
through S-glutathionylation. We provide in-vitro, ex-vivo, and
in-vivo evidence that hBCAT associates with PDI, the inter-
action of which is altered through oxidative and S-nitrosative
stress-induced conditions, where we propose that hBCAT
may have a novel chaperone role in mediating protein fold-
ing. The localization of these proteins to neuronal and endo-
thelial cells of the vasculature of the human brain along with
their co-immunoprecipitation demonstrates that the pro-
posed chaperone role may have physiological relevance.
These findings provide the first evidence that the hBCAT
proteins have oxidoreductase properties similar to PDI and
that these proteins may act as neuro-protectors during the
cellular stress response, which may become compromised by
contributing to protein misfolding, a key feature of neurode-
generative conditions such as AD.
Results
Endogenous PDI-like activity of the hBCAT proteins
in altered redox environments
Both hBCATm and hBCATc catalyzed the refolding of
reduced and denatured RNase (rdRNase) through the in-
troduction of disulfide bonds at a rate significantly greater
than air oxidation alone, with activity at 55%–60% relative to
PDI (Fig. 1A), confirming their oxidase activity. Ovalbumin,
which does not have a redox-active CXXCmotif but contains
free thiols and disulfide bonds, did not exhibit measureable
activity over 24 h. The refolding of rdRNase by the hBCAT
proteins was found to be both time- and concentration de-
pendent and saturated at concentrations of 12 lM (Fig. 1B, C,
respectively). Since protein folding is inherently influenced
by the redox environment (31), we assessed the influence of
various glutathione (GSH) buffers on hBCAT oxidase ac-
tivity. Although GSH buffers alone offer partial refolding of
rdRNase, the oxidase activity of both hBCAT isoforms was
increased two-fold at a 3:1 ratio of GSH/Glutathione dis-
ulphide (GSSG) compared with GSH alone (Fig. 2). How-
ever, as the environment becamemore oxidizing, the oxidase
activity of hBCATm continued to increase relative to
Innovation
The physiological role of the redox active CXXCmotif of
human branched-chain aminotransferase (hBCAT) re-
mains unclear. This report demonstrated a novel functional
role of hBCAT in redox protein folding. Moreover, this is
the first study which reports that hBCATm can bind to
protein disulfide isomerase (PDI) in the human brain and
that PDI is co-localized with hBCATm in mitochondria.
Overall, this has key implications, as both proteins are
modified in Alzheimer’s disease (AD) brains, which could
impact the regulation of protein folding by possibly con-
tributing to the pathogenesis of AD. Understanding the
role of dys-regulated redox mechanisms will assist in the
identification of therapeutic targets for the treatment of
neurodegeneration.
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hBCATc, which itself remained unchanged at these concen-
trations.
In the absence of a GSH buffer, the apparent Vmax was 4.4-
and 2.4-fold less for hBCATm and hBCATc, respectively
(Fig. 3). To investigate the ability of hBCAT proteins to cor-
rectly align mis-paired disulfides, we used scrambled RNase
(scRNase) as a substrate, which is rdRNase with random
disulfide bond formation. Titration of scRNase with 5,5¢-
dithiobis(2-nitrobenzoic acid) (DTNB) before and after oxi-
dation resulted in a loss of thiols to 0.04 lmoles/lmole of
protein with < 1% RNase activity. Although in the presence
of GSH/GSSG the apparent Vmax for refolding of scRNase
was 3.4- and 2.4-fold higher relative to the reaction without
the redox buffer, the dithiol isomerase activity was*50% less
than that reported for their oxidase activity with rdRNase
(Fig. 3). These results demonstrate that the hBCAT proteins
have oxidase and thiol isomerase activity, the kinetics of
which is dependent on the redox environment.
Target site of dithiol-disulfide exchange
To determine the target site of these refolding mechanisms,
active-site cysteine mutants of the hBCAT proteins were as-
sessed for their ability to catalyze the refolding of rdRNase. At
24 h, the oxidase activity of cysteine active-site mutants was
negligible (Fig. 4A), but was recovered by the addition of a
GSH buffer or GSNO, similar to native hBCAT under these
conditions (Fig. 4B, C, respectively). Western blot analysis
confirmed that native hBCAT associates and forms a complex
with RNase (estimated M.Wt. = 53 kDa), which is not evident
in the N-terminal mutant proteins unless S-glutathionylated
(Fig. 4D, E, respectively, arrow). Also observed were
FIG. 1. The human branched-chain aminotransferase
(hBCAT) proteins catalyze the refolding of reduced dena-
tured ribonuclease A (rdRNase). rdRNase (30 lM) was in-
cubated with protein disulfide isomerase (PDI), hBCATm, or
hBCATc (5lM), respectively, in 0.1 M Tris-HCl, pH 7.4, and
1mM EDTA over 24 h (A) and then monitored for the effect
of both time (12, 24 and 48 h) and concentration (4–24 lM) of
each isoform with rdRNase (B, C, respectively). Refolding
was determined using the RNase activity assay, monitoring
the increase in absorbance at 284 nm. Results were expressed
as a % of the activity observed in native RNase preparations.
(A) Dithiol-disulfide exchange activity for PDI (C), hBCATc
(B), hBCATm (;), and rdRNase alone (D). (B, C) Thiol-
disulfide exchange in hBCATc and hBCATm, respectively,
over concentrations, 4, 6, 12, 18, and 24lM at 12 (C), 24 (B),
and 48 (;) h, respectively. Data are the mean– SEM, n = 6.
FIG. 2. Refolding of rdRNase is influenced by the redox
environment. RNase (30 lM) was reduced and denatured as
described in the ‘‘Materials and Methods’’ section and incu-
bated with hBCATm or hBCATc at 10 lM +/ - varying
glutathione (GSH)/Glutathione disulphide (GSSG) ratios
(1:0, 3:1, 1:1, 1:3, and 0:1) in 0.1 M Tris-HCl, pH 7.4, and
1mM EDTA over 24 h. Controls included incubating the
unfolded rdRNase with the same ratios of GSH/GSSG with
an exception to the hBCAT proteins and rdRNase with
hBCAT alone. After 48 h, the contribution of the GSH:GSSG
buffer alone was considerable. Refolding was determined
using the RNase activity assay, which monitored the change
in absorbance at 284 nm. Results were expressed as the
lmoles of active RNase formed/lmole of hBCAT. Data are
the mean – SEM, n= 3.
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multimers when hBCATc was incubated with GSNO or the
GSH buffer (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/ars), which dis-
appeared when RNase was introduced. Multimers were not
reported for hBCATm, suggesting different mechanisms of
action between isoforms and rdRNase. Dimers of rdRNase
were also noted (*). These findings indicate that the thiols of
the CXXC motif are central to their oxidase activity and that
S-glutathionylation is fundamental to this mechanism.
Association of the hBCAT proteins with human PDI
Far Western blot analysis demonstrated that there is a dose-
dependent direct binding of hBCATm and hBCATc with hPDI
(Fig. 5A [i, ii]). Binding is also demonstrated using a reverse dot
blot for PDI with hBCATm and hBCATc, respectively (Fig. 5B
[i, ii], varying concentrations of PDI and Fig. 5C, PDI constant at
7 nmol). Although PDI did not significantly influence hBCAT
transaminase activity (Fig. 5D [i]), incubation of hBCAT with
PDI resulted in an increase in oxidase activity (Fig. 5D [ii]).
Since the initial phase of the reaction occurs earlier relative to
the proteins in their independent reactions, we conclude that
hBCATm acts in a synergistic manner along with PDI in the
initial stages of the refolding reaction but has less influence
during the linear phase (Supplementary Fig. S2). Thus, these
FIG. 3. The apparent Vmax of rdRNase and scrambled
ribonuclease A (scRNase) with hBCATm and hBCATc.
Varying concentrations of rdRNase or scRNase (5–60 lM)
were incubated with hBCATc and hBCATm at 10lM, re-
spectively, in 0.1M Tris-HCl, pH 7.4, with 1mM EDTA +/ -
a GSH buffer (3:1 GSH:GSSG) over 24 h. Refolding was de-
termined using the RNase activity assay, which monitored
the change in absorbance at 284 nm. Lineweaver–Burke plots
were used to determine the apparent Vmax in lmoles min
- 1,
which was converted to lmoles of active RNase formed/
lmole of each respective hBCAT protein. Data are the
mean – SEM, n= 3.
FIG. 4. Thiols of the CXXC motif are integral to the oxidase
activity of hBCAT, which is mediated by S-glutathionylation.
The hBCAT proteins or their respective CXXC mutants,
C315A, C318A (hBCATm), C335S, and C338S (hBCATc)
(12lM), in 0.1 M Tris-HCl, pH 7.4, and 1mM EDTA were
incubated with rdRNase (30lM) for 24 h at room tempera-
ture +/- 1mM S-nitroso-glutathione (GSNO) or GSH buf-
fer (3:1 GSH:GSSG). Refolding was determined using the
RNase activity assay, which monitored the change in ab-
sorbance over time at 284 nm, converted to lmoles of active
RNase formed/lmole of protein. Aliquots of each reaction
were separated on a 4%–12% nonreducing sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sys-
tem, and hBCAT was detected by Western blot analysis
(antibody dilution 1/5000). (A) Active RNase formed by
native hBCAT relative to their mutant proteins. (B) Active
RNase formed by mutant proteins +/ - a GSH redox buffer
or +/- 1mM GSNO, respectively. (C) Active RNase formed
of native hBCAT +/ - a GSH redox buffer or +/ - 1mM
GSNO. (D, E) Coomassie stain and Western blot analysis of
hBCATm and hBCATc with rdRNase under S-glutathionylation
conditions. Data are the mean– SEM, n = 3. Arrows in the box
show that hBCAT has formed a complex with rdRNase.
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proteins can associate with each other in a dose-dependent
manner, and protein folding is influenced by this binding.
Co-localization of hBCATm with PDI and Mia40
in IMR-32 neuronal cells using confocal microscopy
and electron microscopy
Confocal microscopy established that both isoforms dif-
ferentially co-localize with PDI, suggesting that they occupy
the same space within the cell and are interacting (Fig. 6A, B,
merged image). The co-localization of hBCATm/hBCATc
(red channel) and PDI (green channel) is shown as yellow
(merged image) (Fig. 6A, B, respectively). Mander’s correla-
tion coefficients (Mx and My) were derived using Volocity
(Perkin-Elmer) from an average of 15 individual cell images
(6). Mx signifies the correlation of hBCATm/hBCATc co-
localizing with PDI, and the My value reflects the correlation
FIG. 4. (Continued)
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of overlap between PDI and hBCAT. This method quantifies
the signal intensity and can be measured in a range of 0–1,
with 0 indicating no co-localization and 1.0 indicating com-
plete co-localization. The average Mx values for hBCATm
with PDI were 0.675 (Fig. 6A) and 0.648 (Supplementary Fig.
S3), respectively, validated using antibodies specific for PDI
from two independent manufacturers, demonstrating a
strong co-localization between hBCATm and PDI; whereas
the My value, a measure of PDI co-localizing with hBCATm,
was recorded at 0.31. The co-localization of hBCATc with PDI
was not as strong with an Mx value of 0.29 recorded (Fig. 6B,
merged image). In addition, hBCATm showed co-localization
with Mia40 (Mx= 0.849, Fig. 6C), a mitochondrial-specific
redox protein that also co-localized with PDI with an Mx
value of 0.96, confirming that this co-localization is specific to
the mitochondria (Fig. 6D). The My correlation for PDI with
Mia40 was 0.23. Together, these data indicate that in the mi-
tochondria, the co-localization of hBCATmwith PDI is strongly
correlated but relative to the whole cell, co-localization of PDI
with these mitochondrial proteins (that will account for ER
expression of PDI); the signal is weak, illustrating that the
co-localization is clearly specific to the mitochondria.
Electron microscopy independently validated that
hBCATm can co-localize with PDI in the mitochondria as
determined by calculating distances between cellular pro-
teins, where a distance of approximately 50 nm apart is con-
sidered co-localization, which factors the distance of the
antibodies and gold particles (64). IMR-32 cells showed a
predicted distribution of hBCATm and Mia40 within the mi-
tochondria (distance apart = 9.46–11.59 nm), suggesting co-
localization (Fig. 7A). Validation that PDIwas also detected in
the mitochondria was determined using Mia40 as a mito-
chondrial control protein (Fig. 7B). In a separate section, PDI
was observed in themitochondria and in close proximity with
hBCATm (distance apart 11.16–15.85 nm), validating our
confocal microscopy data that indicated these two proteins
were occupying the same space, suggesting an interaction
(Fig. 7C). It is also important to note the detection of
hBCATm in the intermembrane space (Fig. 7C). These studies
were validated using antibodies from several suppliers
FIG. 5. The in-vitro association of the hBCAT proteins with hPDI. (A) Human PDI (hPDI) (0.1–0.5 lg) was applied to a
nitrocellulose membrane. After blocking, 5lg/ml of hBCATm (i) and hBCATc (ii), respectively, were incubated with hPDI.
Bound hBCAT was detected by using anti-hBCAT (antibody dilution 1/1000). (B) Each respective hBCAT protein [hBCATm
(i) and hBCATc (ii)] (1.0–3.5 lg) was applied to a nitrocellulose membrane. After blocking, 5 lg/ml of hPDI was incubated
with each respective hBCAT isoform. Bound PDI was detected by using anti-PDI-2 (antibody dilution 1/1000). (C) hPDI at
0.4 lg was incubated with hBCATm (0.3–25 lg) (i) and hBCATc (10–30lg) (ii). Bound hBCAT was detected using anti-
hBCAT (antibody dilution 1/1000). (D)(i) The hBCAT transaminase activity (Units/mg) of both isoforms incubated with
PDI +/- a GSH buffer (3:1 GSH:GSSG). (D)(ii) PDI and each respective hBCAT isoform were incubated with rdRNase
(30 lM), and aliquots were removed at 24 h to determine the effect on RNase folding. Active RNase formed/lmole of protein
catalyzed by PDI, hBCAT, and PDI +hBCAT, respectively. Data are the mean– SEM, n = 3.
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FIG. 6. The mitochondrial
hBCAT co-localizes with
PDI and Mia40. IMR-32 cells
were fixed for immunostain-
ing as described in the ‘‘Ma-
terials and Methods’’ section
using primary antibodies: (A,
B) anti-hBCATm-1, anti-
hBCATc-1 (1/500 dilution),
and anti-PDI-1 (1/150 dilu-
tion). (C) anti-hBCATm-2 (1/
250 dilution) and anti-Mia40
(1/100). (D) anti-PDI-1 (1/
150 dilution) and anti-Mia40
(1/100 dilution). Secondary
antibodies: goat anti-rabbit
Alex Fluor 568 (hBCATc-1,
hBCATm-1, Mia40 [1/500 di-
lution]) and goat anti-mouse
Alex Fluor 488 (PDI-1 and
hBCATm-2, [1/500 dilution]).
Slides were washed and
mounted in 300 nM 4¢,6
diamino-2-phenylindole (DAPI)
in glycerol. Mander’s correla-
tion coefficient (Mx) was
used to statistically assess the
co-localization of hBCAT
proteins with PDI and Mia40,
respectively and also between
PDI and Mia40. The Mander’s
co-localization coefficients
were derived using Volocity
(Perkin-Elmer) from an aver-
age of 15 individual cell im-
ages. (A) PDI (Green)+
hBCATm (red). (B) PDI
(Green) +hBCATc (red). (C)
hBCATm (red)+Mia40 (Green).
(D) PDI (Green)+Mia40
(Red). Merged images show
yellow, where co-localization
is observed as indicated by
the arrows in each image. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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(Supplementary Fig. S4), demonstrating that PDI is found in
the mitochondria of neuronal cell cultures and is co-localizing
with hBCATm.
Co-immunoprecipitation of hBCATm
and PDI from IMR-32 cells
Direct binding of hBCATm with PDI was demonstrated
using immunoprecipitation (IP) analysis, where antibodies
specific for hBCATm and HIS-tagged hBCATm isolated PDI
from neuronal cell lysates transfected with hBCATm-
pDEST26 Gateway destination vector (HIS-tagged) and
homogenates from human brain (Fig. 8). The expected 57 kDa
PDI proteinwas precipitatedwith anti-hBCATmand detected
using Western blot analysis using anti-PDI (Fig. 8A [i]). This
band corresponded to the bands observed in whole cell ly-
sates and pure overexpressed hPDI protein. The absence of a
band in the control IP samples confirms that the proteins
eluted are specific to anti-hBCATm.Moreover, using the same
conditions, PDI was co-immunoprecipitated from human
brain samples using anti-hBCATm (Fig. 8A [ii]). To further
validate the specificity of this interaction, neuronal cells were
transfected with HIS-tagged hBCATm and shown to specifi-
cally interact with PDI, where the concentration of hBCATm
in the purified complex is *31 nM with 16 nM of PDI (as
estimated from pure hBCATm and PDI, respectively), indi-
cating a 2:1 ratio of hBCATm to PDI (Fig. 8B). These studies
demonstrate that PDI was co-purified with hBCATm, sug-
gesting that hBCATm directly binds to PDI in neuronal cells
and, more importantly, in the human brain.
Co-localization of hBCATm with PDI in IMR-32
neuronal cells is reduced under increased
oxidative stress
The co-localization of hBCATm with PDI decreased
(Mx= 0.675 to 0.159) when the cells were incubated with in-
creasing concentrations of hydrogen peroxide or GSNO, re-
spectively (Fig. 9A). Incubation of IMR-32 cells with GSNO
did not impact the association between hBCATc and PDI;
however, with hydrogen peroxide, the Mx value of hBCATc
with PDI increased from 0.29 to 0.635 (Fig. 9B). Electron mi-
croscopy also shows that hBCATm is no longer observed in
close proximity to PDI when the cells are treated with 100 lM
of hydrogen peroxide (Fig. 9C). The increased association of
hBCATm with the mitochondrial membrane under these
conditions should be noted. These studies taken together
provide evidence that hBCAT can associate with other redox-
sensitive proteins such as PDI and that these associations are
altered when the cells are exposed to increased oxidative
stress.
Expression of hBCAT proteins and PDI
in the human brain
To ascertain whether the hBCAT proteins were expressed
in the same human brain, cells as PDI serial sections from the
temporal and cerebellum of human brains were analyzed
using antibodies that were specific for each respective protein.
In agreement with previous studies (28), hBCATc is neuronal
specific (Fig. 10A, B) and here using serial sectioning, we show
FIG. 7. Localization of
hBCATm, Mia40, and PDI in
the mitochondria of IMR-32
cells. Electron micrograph of
IMR-32 cells expressing, (A)
hBCATm and Mia40 la-
beled with anti-mouse-10 nm
(hBCATm-2–black arrow-
heads) and anti-rabbit-6 nm
(Mia40–white arrowheads) gold-
conjugated secondary anti-
bodies. (B) PDI and Mia40
labeled with anti-mouse-
10 nm (PDI-1–white arrow-
heads) and anti-rabbit-6 nm
(Mia40–black arrowheads)
gold-conjugated secondary
antibodies. (C) hBCATm and
PDI labeled with anti-mouse-
10 nm (hBCATm-2–black
arrowheads) and anti-rabbit-
6 nm (PDI-2–white arrowheads)
gold-conjugated secondary
antibodies. Scale bar: A–C
(50 nm).
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that PDI is expressed in the same neuronal cells with a similar
pattern of distribution (Fig. 10C, D). Interestingly, strong
staining of PDI was also indicated in the endothelial cells of
the vasculature, where hBCATm is predominantly expressed,
in addition to some neuronal staining (Fig. 10E, F and G, H,
respectively). These studies confirm that PDI is expressed in
the same brain cells as the hBCAT isoforms and alongwith the
co-immunoprecipitation studies, indicate that these proteins
have the potential to interact in vivo.
Discussion
Accumulation of mis-folded proteins is the hallmark of
several neurodegenerative conditions, including Alzhei-
mer’s, Parkinson’s, Huntington’s, and prion diseases (9, 44,
71). However, the mechanisms that underpin this are not
clearly defined. Similar to PDI and other oxidoreductases,
the mammalian hBCAT proteins have a conserved CXXC
motif, where the thiols of the CXXC motif can recycle be-
tween an intra-molecular disulfide bond (inactive) and the
reduced dithiol (active) (61, 73). The present study demon-
strates that hBCAT proteins catalyze the insertion of
disulfide bonds into rdRNase-releasing active RNase, with
the active cysteines playing a central role in this mechanism.
Several other CXXC redox-sensitive proteins such as thior-
edoxin and platelet integrin alpha IIbbeta 3 have also been
reported to have endogenous thiol disulfide isomerase ac-
tivity (37, 40, 48). Inactivity reported for the N-terminal
mutant proteins can be explained by their inability to form
an intermediate with RNase, suggesting that the N-terminal
cysteine is essential for the first step in forming a mixed
disulfide with RNase. The N-terminal cysteine residues of
both isoforms are central to their transaminase activity, as
mutation of the reactive cysteine results in a complete loss in
hBCAT activity (16). A number of the PDI family members,
namely, ERp27, ERp28, PDILT, and TMX2, are missing in the
surface exposed to N-terminal cysteine and similar to our N-
terminal mutants, lack thiol disulfide isomerase activity, dem-
onstrating the importance of this residue for catalysis (21, 65).
Even though the C-terminal mutant can potentially take
part in the first step of the reaction, this intermediate may get
trapped, as the reaction cannot subsequently progress to
complete oxidation, as evidenced by the inability of these
mutants to form active RNase, suggesting that this residue is
required for substrate escape. This concept has previously
been described for other systems, where stable intermediates
result when the C-terminal residue is absent, such as that
reported for ERp44, which results in the retention of these
proteins in the ER, impacting protein function (3, 4). How-
ever, here, when S-glutathionylated, the single cysteine
mutants have oxidase activity and form intermediates that
are comparable to native proteins. This shows that either
cysteine residue when forming a mixed disulfide with GSH
can catalyze disulfide bond formation and implies that re-
active thiols in other proteins subject to S-glutathionylation
may also participate in oxidase activity, even if the CXXC
motif is not present. Single active-site thiol disulfide ex-
change has also been explored and found to have effective
activity for single mutants of the bacterial isomerase equiv-
alent DsbA (69).
The increased oxidase activity of hBCATm relative to
hBCATc reported as the environment became less reducing
is consistent with their measured Em values ( - 310 and
- 225mV, for hBCATc and hBCATm, respectively) (14).
This indicates that while both proteins are reducing in na-
ture, hBCATm is the less so of the two, and has a similar Em
value to those reported for the human mitochondrial iso-
forms of the repair enzymes, thioredoxin and glutaredoxin
(52, 66, 67). Taken together, we propose that hBCAT oxido-
reductase activity is initiated through the S-glutathionylation
of the hBCAT protein at the N-terminal cysteine position.
Under nucleophilic attack, the reactive thiolate anion of
RNase forms an inter-disulfide bond with S-glutathionylated
hBCAT. Along with the C-terminal cysteine, the second thiol
of RNase forms a disulfide bond, releasing RNase (S-S).
Without the thiol at the C-terminal position, the mixed dis-
ulfide intermediate cannot be released and remains fixed
to the N-terminal residue. Although S-glutathionylation is
clearly involved in maximizing oxidase turnover, it is likely
that other chaperones are involved in this mechanism in
cells. A plausible candidate is human Ero1, a flavin adenine
dinucleotide-binding oxidase, which has been proposed to
act in part to provide oxidizing equivalents to PDI (24, 54).
However, recent studies using knock-out Ero-1 have shown
little physiological consequence, leading to debate as to
whether Ero-1 is the primary donor of oxidizing equivalents
FIG. 8. Immunoprecipitation of hBCATm with PDI from
IMR-32 cell lysates and human brain homogenates. (A) (i)
IMR-32 cell lysates (800 lg) and (ii) 800lg of human brain
tissue homogenate were immunoprecipitated with
hBCATm-2 raised in mouse (specific immunoprecipitation
[IP]) and rabbit IgG (control IP) using protein G MagSepa-
harose beads. (B) IMR-32 cells (800 lg) transfected with
hBCATm-pDEST26 Gateway destination vector (HIS tagged)
(Two standard concentrations of hBCATm were included
( + = 5 ng and + + = 10 ng of hBCATm)). PDI was detected
using anti-mouse HRP (1/2000). Co-purification of PDI was
assessed by immunoblotting with anti-PDI-2 (1/1000). These
images are representative of three independent repeat ex-
periments.
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or whether other mechanisms exist that substitute for its
absence in these models (74). Lappi and Ruddock have re-
cently revaluated the role of GSH buffers in this system and
strongly advocate their physiological role in protein folding,
in particular calling for further investigations into the phys-
iological role of GSSG in the ER (38). The pathways for di-
thiol-disulfide exchange are complex and have not been
entirely elucidated. Single thioredoxin-like domains of PDI
have redox activity but poor isomerase activity, suggesting
that a second CXXC motif is required for maximal dithiol-
disulfide isomerase activity (19). This is possibly the case
seen here for hBCAT, which shows that although they can
undergo cycles of reduction followed by correct alignment of
disulfide bonds, their isomerase activity is significantly less
than their oxidase activity, and likely to be less significant
than its oxidoreductase activity. However, in cells, the di-
rection of the reaction to oxidation or reduction will depend
on the overall Eh, the redox state of the CXXC motif of the
hBCAT proteins, its microenvironment, and also other
chaperone and redox repair systems present, which requires
further investigation.
Co-localization of hBCATm with PDI in neuronal cells
was curious, as PDI is considered to be largely associated
with the ER; however, it has also been localized to mito-
chondria and the cytosol. Although the cytosolic and mito-
chondrial proteins are the two key mammalian isoforms,
other spliced variants of hBCAT homologous to hBCATm
have been described, namely a novel alternative splice var-
iant found in placental tissue and a splice variant that acts as
a co-repressor of thyroid hormone nuclear receptors (39, 59).
It remains unknown whether another hBCAT isoform could
exist and reside in the ER or whether the predominant iso-
forms participate in their PDI-like activity elsewhere in the
cell, as disulfide bond formation can also occur in mito-
chondria and outside the cell in the blood (1, 36). However,
here, using Mia40 as a control mitochondrial protein, PDI
was located to the mitochondria using electron microscopy
and in close proximity ( £ 50 nm apart) to hBCATm, sug-
gesting co-localization. These findings along with confocal
microscopy confirm that the interaction between PDI and
hBCATm is specific to the mitochondria. Co-immunopre-
cipitation assays validated direct binding, not only in neu-
ronal cell cultures but also from human brain tissue.
Moreover, the fact that PDI was identified in neuronal and
endothelial cells, where both hBCATs reside, suggests the
clear potential for this interaction to be physiologically
relevant. We hypothesize that hBCATm and PDI could op-
erate through dithiol-disulfide exchange, and hBCATm
could potentially act as a chaperone to assist PDI in facili-
tating protein folding or in its own capacity act as a dithiol-
disulfide oxidoreductase.
The importance of molecular chaperones and PDI is re-
flected in their role for the correct folding of proteins and the
elimination of misfolded or irreversibly damaged proteins
from the cell (44). Accumulation of aggregates such as a-
synuclein and synphillin-1 in Parkinson’s disease and
amyloid-b and hyper-phosphorylated tau in AD along with
inclusion bodies associated with amylotrophic lateral sclero-
sis (ALS), and prion diseases are common features of these
neurodegenerative conditions (35, 44). Molecular chaperones
such as the heat shock proteins (HSP70 and HSP90, in par-
ticular) and PDI are up-regulated in response to cellular stress
and believed to function as neuroprotectors in these diseases
[reviewed in Andreu et al. (2)]. These systems operate as a
network with the unfolded protein response, which is di-
rected to the clearance of modified or incorrectly folded pro-
teins. However, although these systems are up-regulated,
evidence suggests that oxidative and S-nitrosative stress may
impact protein function, thus compromising their neuropro-
tective role (46, 47, 56, 63). One such example is a study by
Uehara et al., which showed that PDIwas S-nitrosylated in the
brains of patients with Parkinson’s disease and AD (63).
Modeling of this mechanism in SH-SY5Y cells resulted in the
accumulation of protein aggregates, supporting their hy-
pothesis that S-nitrosylated PDI contributes to protein mis-
folding and has the potential to play a role in the pathogenesis
of AD. In a separate study, PDI-SNO was also detected in the
spinal cord of ALS patients.
In rat models, up-regulation of hBCATc has been related
to cell survival. A report by Kholodilov et al. showed an
increase in mRNA expression of BCATc in the substantia
nigra of rats after developmental striatal target injury (34).
Although this correlated with cell death, the neurons that
were immunopositive for BCATc had normal physiology
and rarely contained apoptotic chromatin, suggesting that
BCATc played a neuroprotective role. Furthermore, admin-
istration of brain-derived neurotrophic factor (role in neu-
ronal survival, growth, and differentiation) after a lesion of
the visual cortex in newborn rats resulted in the up-regulation
of BCATc (10). Increased expression was also observed in the
brain of transgenic rats overexpressing BDNF in a time- and
region-dependent manner (43). Collectively, these studies
support the role of the BCAT proteins in maintaining neuronal
survival. Recent studies by our group have demonstrated that
both hBCAT isoforms show increased protein expression (up to
140% for hBCATm) in the brain of patients with AD relative to
FIG. 9. Co-localization of hBCATm with PDI in IMR-32 neuronal cells is reduced under increased oxidative stress. IMR-
32 cells were treated with 50 and 100 lM of hydrogen peroxide and 100 and 500lM GSNO for 30min, respectively. Cells
were subsequently fixed for immunostaining as described in the ‘‘Materials and Methods’’ section using primary antibodies:
(A, B) anti-hBCATm-1, anti-hBCATc-1 (1/250 dilution), and anti-PDI-1 (1/150 dilution). Secondary antibodies: goat anti-
rabbit Alex Fluor 568 (hBCATc-1, hBCATm-1, [1/500 dilution]) and goat anti-mouse Alex Fluor 488 (PDI-1 [1/500 dilution]).
Slides were washed and mounted in 300 nM DAPI in glycerol. Mx was used to statistically assess the co-localization of
hBCAT proteins with PDI under altered redox conditions. Mander’s co-localization coefficients were derived using Volocity
(Perkin-Elmer) from an average of 15 cell images. (A) hBCATm with PDI under oxidizing and S-nitrosylating conditions. (B)
hBCATc with PDI under oxidizing and S-nitrosylating conditions. PDI (Green) +hBCATm/hBCATc (red). Merged images
show yellow where co-localization is observed. (C) Electron micrograph of IMR-32 cells treated with 100lM hydrogen
peroxide for 30min expressing hBCATm and PDI labeled with anti-mouse-10 nm (hBCATm-2–black arrowheads) and anti-
rabbit-6 nm (PDI-2–white arrowheads) gold-conjugated secondary antibodies. Scale bar: C (50 nm). To see this illustration in
color, the reader is referred to the web version of this article at www.liebertpub.com/ars
‰
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matched control patients (n= 30, frontal and temporal region)
(Conway, unpublished data). Based on previous studies, we
suggest that the expression of hBCAT is increased in response
to changes in the cellular redox environment, to assist in neu-
ronal protection. We speculate that since the hBCAT proteins
have oxidoreductase activity and can refold proteins, theymay
play a role in facilitating thiol-disulfide exchange either inde-
pendently or as a redox chaperone to PDI or Mia40. However,
similar to PDI, the hBCAT proteins are regulated through ox-
idation and S-nitrosylation (13, 15, 16), such that under in-
creased cellular stress, their proposed neuroprotective role, and
their association with these proteins would be affected.
Therefore, knowing that the function of these proteins is com-
promised under cellular stress highlights the impact during
pathogenic conditions where protein misfolding features. Fu-
ture studies will investigate and characterize the role of redox-
modified hBCAT with potential redox partners and protein
folding in cells.
In conclusion, we have identified that hBCATproteins have
novel dithiol-disulfide isomerase activity that plays a role in
protein folding. We demonstrate that S-glutathionylation is
not only present to protect the function of a redox-sensitive
protein, a concept held in high regard by most groups, but it
has also shown value mechanistically and was shown here to
be integral to the refolding of proteins catalyzed by hBCAT.
Moreover, we have demonstrated that hBCATm is localized
with other redox-sensitive proteins such as PDI and Mia40 in
the mitochondria. These findings may have physiologically
FIG. 10. Co-localization of hBCATc
and hBCATm with PDI in the same
cell types of the human cerebellum,
temporal lobe, and hippocampus. Se-
rial sections that were 7lm in thick-
ness were taken from each brain region
and subsequently immunolabeled as
described. Antibodies specific to
hBCATc-1 and hBCATm-1 and PDI-2
were used to identifiy each respective
protein. A–D show localization of
hPDI and hBCATc to the purkinje cells
(arrowhead) of the cerebellum. E–H
shows the localization of hPDI and
hBCATm to the endothelial layer of
vessels (arrowhead) on serial sections of
the temporal cortex (E1G) and the
CA4 region of the hippocampus
(F1H). Also shown in E1F is PDI la-
beling of neurons of the temporal cor-
tex (E) and granule cells (*) of the
dentate nucleus (F). Scale bars: A, C
(100 lm); B, D, E, F, G, H (20lM). To
see this illustration in color, the reader
is referred to the web version of this
article at www.liebertpub.com/ars
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relevant implications in the human brain, but more impor-
tantly in protein misfolding, a key mechanism that is associ-
ated with AD pathology.
Materials and Methods
Materials
Cytidine 2¢,3¢–cyclic monophosphate (cCMP), RNase,
bovine PDI, nonessential amino acids, fetal calf serum,
100 · penicillin/streptomycin solution, glutaraldehyde,
sodium borohydride, sodium cacodylate, Tween20, and
Triton X-100 were obtained from Sigma-Aldrich (Dorset,
UK). RPMI 1640 was obtained from Lonza (Gloucestershire,
UK). Human PDI (hPDI) was obtained from Cambridge
Bioscience (Cambridge, UK). IMR-32, neuroblastoma cell
line (ATCC CCL-127) was obtained from LGC Promochem
(Middlesex, UK). NuPAGE LDS sample buffer (4· ), Nu-
PAGE Novex 4%–12% Bis-Tris 1mm gel, 20· NuPAGE
MES SDS running buffer, and 20· NuPAGE Transfer Buffer
were obtained from Invitrogen (Paisley, UK). Electron mi-
croscopy (EM) grade paraformaldehyde was purchased from
BDH (Leicestershire, UK). Acetylated bovine serum albumin
(BSA) (10%) was purchased from Aurion (Wageningen, The
Netherlands). Peroxidase, substrate 3,3¢-diaminobenzidine
(DAB), donkey serum, 4¢,6-diamino-2-phenylindole (DAPI)-
containing mounting medium, biotin-labeled secondary anti-
body raised to IgG, and avidin (Vectastain ABC kit) were
purchased from Vector Labs (Peterborough, UK). Hematox-
ylin, Clearene, and Clearium were purchased from SurgiPath
(Peterborough, UK). BM chemiluminescent horse radish per-
oxidase (HRP) substrate was purchased from Roche (West
Sussex, UK). Hyperfilm was obtained from GE Healthcare
(Cardiff, UK). All antibodies used in these studies are sum-
marized in Supplementary Table 1. All other materials were
purchased from Fisher Scientific (Loughborough, UK).
Preparation and activity of rdRNase and scRNase
Twenty milligrams of RNase was incubated with 150mM
DTT and 6 M guanidine hydrochloride over 18 h at room
temperature (RT) in 0.1 M Tris, pH 8.6, desalted into 0.01N
HCl, and stored under argon at - 80C. To prepare scRNase,
rdRNase in 6 M guandine-HCl was adjusted to pH 8.6 with
solid Tris, sparged with oxygen for 1 h at RT, and allowed to
re-oxidise in the dark for 4 days. The thiol concentration of
scRNase was assessed before and after oxidation by titration
with DTNB (18). RNase activity was determined by the pro-
tein refolding assay (detailed in 41, 42, 49, 50). Briefly, a final
concentration of 1.4 lM RNase was added to 0.44mM cCMP
that was prepared in 0.1 M 4-morpholinepropanesulfonic
acid, pH 7.0 with the increase in absorbance at 284 nm mon-
itored over 10min.
Reactivation of rdRNase catalyzed by native hBCAT
and mutant proteins
All hBCAT and mutant proteins were exchanged into 0.1
M Tris-HCL, pH 7.4 with 1mM EDTA before incubation
with rdRNase. Typically, for each refolding assay, 30 lM
rdRNase was incubated at RT with test protein and aliquots
were removed to assess RNase activity at 24 and 48 h. The
effect of time (12–48 h) and concentration (4–24 lM) on this
reaction was assessed under these conditions. The redox
environment was also varied using five different GSH/
GSSG ratios (1:0, 3:1, 1:1, 1:3, and 0:1). In a separate experi-
ment, the hBCAT proteins were pretreated with 500 lM
GSNO for 30min at RT before incubation with rdRNase.
Control samples for the hBCAT and mutant pro-
teins – rdRNase, rdRNase alone, for each GSH/GSSG ratio,
and GSNO were included for each time point and each
concentration. Subsequently, using a GSH/GSSG ratio of
3:1, the apparent Vmax for rdRNase and scRNase was
determined by holding hBCAT at 10 lM with the substrate
(either rdRNase or scRNase) concentration between 5 and
60 lM. A standard curve was generated from the initial rates
of a range of RNase concentrations (0–4 lM). Using the slope,
the concentration of active RNase formed/lM of proteinwas
calculated. Western blot analysis of these samples was car-
ried out as described in Supplementary Data.
Far Western immunoblotting
Human BCAT (1.0–3.5 lg, Fig. 5A) or hPDI (0.1–0.5 lg, Fig.
5B and constant at 0.4 lg, Fig. 5C) was applied to a nitrocel-
lulose membrane. After blocking with 1 · Tris buffer saline
with tween (TBST) containing 5% BSA for 1 h at RT, the
membrane was incubated with 5lg/ml of PDI, hBCATc, or
hBCATm, respectively, for 90min at 37C, with shaking at
100 rpm. After washing, bound hBCAT was detected by in-
cubating with anti-hBCAT (1/1000 dilution) or for the
hBCATs, anti-PDI-2 (1/1000) shaking, overnight at 4C.
Bands were visualized using BM chemiluminescent HRP
substrate and exposed to HyperFilm.
Immunocytochemistry of hBCAT and PDI
in neuronal cells
IMR-32 cells were allowed to reach 70%–80% confluence
and treated +/ - hydrogen peroxide (50–100 lM) and GSNO
(100–500 lM) for 30min, respectively, at 37C in a humidified
incubator that was adjusted to contain 5% carbon dioxide.
After serial washes, the cells were fixed with 0.25% glutaral-
dehyde and permeabilized with 0.2% Triton X-100 for 20min
at RT in a 0.1M sodium cacodylate buffer, pH 7.4 adjusted to
contain 0.1 M sucrose. The cells were further treated by a
succession of washes with sodium borohydride (1mg/ml in
PBS) and blocked in 3% BSA overnight before incubatingwith
primary antibodies, anti-hBCATc, anti-hBCATm-1 (1/500),
anti-PDI-1 (1/150 dilution), anti-PDI-2, anti-Mia40 (1/100),
and anti-hBCATm-2 (1/250), respectively, for 1 h at RT. After
serial washes, the cells were incubated with goat anti-rabbit
Alexa Fluor 568 (hBCATc, hBCATm-1, PDI-2, andMia40, 1/
500 dilution) and goat anti-mouse Alexa Fluor 488 (PDI-1 and
hBCATm-2, 1/500 dilution) for 1 h at RT. Slides were washed
in cacodylate buffer andmounted in 300 nMDAPI in glycerol.
The Mander’s correlation coefficients (Mx and My) were de-
rived using Volocity (Perkin-Elmer) from an average of 15
individual cell images.
Electron microscopy of hBCAT and PDI
in neuronal cells
Cells that had been previously incubated +/- 100 lM of
hydrogen peroxide for 30min were fixed in a final concen-
tration of 2% formaldehyde and 0.2% glutaraldehyde in
phosphate buffer and processed according to the Tokuyasu
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method for cryosectioning (55, 60). Seventy nanometre sec-
tions were prepared at - 120Cwith 1%methylcellulose in 1.2
M sucrose and transferred onto carbon-coated copper mesh
grids. The sections were labeled with primary antibodies to
anti-hBCATm-1-3, anti-Mia40, anti-PDI-1, and anti-PDI-2 (1/
10), respectively. Gold-labeled secondary antibodies, 6 and
10 nm (1/20), respectively, were incubated for 1 h at RT. All
antibodies were prepared in 0.1% acetylated BSA. The sec-
tions were counterstained with 0.3% uranylacetate in 2%
methylcellulose on ice and imaged on a CM10 (Philips) elec-
tron microscope.
Mammalian expression of HIS-tagged hBCATm
using Gateway technology
According to the manufacturer’s instructions, the LR re-
combination reaction contained 50–100 ng of purified
hBCATm pENTR221 entry vector (synthesized and pre-
pared by GeneArt, Life Technologies), 150 ng of pDEST26
Gateway destination vector and TE buffer, pH 8.0 was used to
adjust the final volume to 8ll. Positive controls containing
100 ng pENTR-gus with 150 ng pDEST26 and negative con-
trols containing 150 ng of purified BCATm pENTR221 with
150 ng pDEST26 were also included. The reaction was started
with 2ll of LR Clonase II enzyme mix (with exception to the
negative control). The samples were incubated in a PCR hot
block at 25C for 3 h. To stop the LR reaction, 1 ll of proteinase
K solution was added and incubated at 37C for 10min. The
completed LR reaction (1ll) was subsequently transformed
into Library Efficiency DH5a Cells according to the man-
ufacturer’s instructions. Plasmids were purified using the
PureLinkHi-Pure plasmid mini-prep purification according
to the manufacturer’s instructions, and restriction analysis
was used to confirm correct orientation of the insert. IMR-32
cells were subsequently transfected with hBCATm expression
plasmid using jetPRIME transfection reagent (Polyplus) and
following the protocol prescribed by the manufacturers.
Controls included transfection reagent alone, cell only, and
pcDNA3-EGFP to assess transfection efficiency.
Co-immunoprecipitation of hBCATm with PDI from
IMR-32 cell lysates and human brain homogenates
Cell lysates (800 lg) from IMR-32 cells or brain homoge-
nates (800lg) were incubated with anti-hBCATm-protein G
Mag Sepharose beads overnight. Total cell lysates, bound
protein, and pure overexpressed hPDI were separated on
a 6.5% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) gel and transferred onto a nitrocellulose
membrane for Western blot analysis as described earlier.
Primary antibody (1/1000 for hPDI) was prepared in 5%
nonfat milk powder in 1 · TBST and incubated overnight at
4C before several washes with 1· TBST. Secondary anti-
body, mouse anti-rabbit light chain specific (1:2000) was
added for 1 h at RT and then washed with 1 · TBST followed
by a 1 h incubation with anti-mouse HRP (1/2000). The pos-
itive bands were visualized using BM chemiluminescent HRP
substrate and imaged using hyperfilm.
Immunohistochemistry of the hBCAT isoforms and PDI
The studywas approved by theNorth Somerset and South
Bristol Research Ethics Committee. All brain tissue used in
this study was from brains donated with consent to the
SouthWest Dementia Brain Bank in the University of Bristol,
UK. Serial sections (7 lm) were taken from the temporal and
cerebellum brain regions, placed in a 60C oven overnight
before immunohistochemical staining, and subsequently
dewaxed in clearene (2 · 5min) and dehydrated in 100%
ethanol (2 · 3min). Endogenous peroxidase was quenched in
0.09% hydrogen peroxide/methanol solution for 30min at
RT. The slides were pretreated with citrate buffer (10mM
sodium citrate, 0.05% Tween 20, pH 6.0), then washed
(2 · 3min) in PBS containing 0.154 M NaCl, 1.86mM
Na2H2PO4.2H2O, 7.48mM Na2HPO4.12H2O, pH 7.1, and
blocked with 10% horse serum in PBS for 20min at RT.
Sections were incubated at RT overnight with primary an-
tibody (1/6000 for both hBCAT isoforms) in PBS. The sec-
tions were washed in PBS (2 · 3min) and incubated with
biotinylated antibody to IgG for 20min (Vectastain ABC kit).
The slides were washed again in PBS (2 · 3min) and incu-
bated with the avidin-biotin complex in PBS for 20min
(Vectastain ABC kit). Slides were developed with DAB/
H2O2 in distilled water (DAB substrate kit) for 10min before
immersion in copper sulfate solution (16mM CuSO4.5H2O,
0.123 M NaCl) for 4min, and counterstained with Harris’
hematoxylin (25% Gill haematoxylin). The slides were de-
hydrated in 100% ethanol (2 · 5min), cleared in 100%
Clearene (2 · 3min), and mounted in Clearium. Sections
were viewed and imaged on a Nikon Eclipse 50i or a Leica
DMR microscope.
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Abbreviations Used
AD¼Alzheimer’s disease
ALS¼ amylotrophic lateral sclerosis
BCKDH¼ branched chain keto acid dehydrogenase
complex
BSA¼ bovine serum albumin














rdRNase¼ reduced denatured ribonuclease A
RT¼ room temperature
scRNase¼ scrambled ribonuclease A
TBST¼Tris buffer saline with tween
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